Get the Stockscreener App
7.66
0.13%
0.010
After Hours:
7.62
-0.04
-0.52%
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Sumitomo Mitsui Trust Group Inc. Decreases Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - AOL
Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Investors Purchase Large Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Recursion Pharmaceuticals (NASDAQ:RXRX) - MarketBeat
Stock Traders Buy Large Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by SG Americas Securities LLC - MarketBeat
Recursion Pharmaceuticals’ (RXRX) AI Approach to Drug Discovery Shows Progress - Markets Insider
Why Recursion Pharmaceuticals (RXRX) Stock Went Down On Thursday? - MSN
Where Recursion Pharmaceuticals Stands With Analysts - Benzinga
Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note - MSN
March 28th Options Now Available For Recursion Pharmaceuticals (RXRX) - Nasdaq
BlackRock, Inc. Expands Stake in Recursion Pharmaceuticals Inc. - GuruFocus.com
Recursion Presents Phase 2 Data for REC-994 in CCM in - GlobeNewswire
Recursion Announces Promising Clinical Data on Lead AI-Based Drug Candidate for Brain Disease - Genetic Engineering & Biotechnology News
Institute for Wealth Management LLC. Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Inside Recursion’s Pipeline: Najat Khan On AI, Data Science And Biotech Innovation - Citeline News & Insights
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 9%Here's Why - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.6%Should You Sell? - MarketBeat
Why Recursion Pharmaceuticals Stock Is Tumbling Thursday - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 9% HigherHere's Why - MarketBeat
Objective long/short (RXRX) Report - Stock Traders Daily
3 Monster Stocks to Hold for the Next 10 Years - Yahoo Finance
Biotech Stocks To ConsiderJanuary 31st - MarketBeat
How Is The Market Feeling About Recursion Pharmaceuticals? - Benzinga
As Pipeline Advances, Recursion Expands AI Focus to Clinical Trials - Genetic Engineering & Biotechnology News
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo Finance
Institutional owners may consider drastic measures as Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) recent US$130m drop adds to long-term losses - Yahoo Finance
Is Recursion Pharmaceuticals (RXRX) the Cheap AI Stock to Buy in 2025? - MSN
12 Cheap AI Stocks to Buy in 2025 - Insider Monkey
AI Pharma: 2 Paths to AI-Powered Drug Investment - MarketBeat
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):